Michael J. McCall - Concepedia

Concepedia

Author

Michael J. McCall

University of California, Davis

Also Known As

M J McCall, M. J. MCCALL, M. J. McCall, M.J. McCall, MICHAEL J. MCCALL, McCall, Michael J.; Brandvold, Timothy A.; Elliott, Douglas C., Michael J McCall, Michael J. McCall, Michael J. Mccall

37

Publications

1.8K

Citations

19

H-Index

61

Concepts

All Affiliations

University of California, Davis Stanford University VA Palo Alto Health Care System United States Department of Veterans Affairs University of California Davis Medical Center

MJ

About

Michael J. McCall is an author at University of California, Davis specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	1.4K
2	Engineering	5	5	326
3	Natural Sciences	4	4	368
4	Health Sciences	2	2	50
5	Allergy	1	1	33

Michael J. McCall

×

21

Publications

1.8K

Citations

19

H-Index

	Year	Citations
Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions Claude F. Meares, Michael J. McCall, Dayton T. Reardan, Analytical Biochemistry Metal IonsBiochemistryMedicineBioanalysisBioconjugation	1984	375
Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. David A. Goodwin, Claude F. Meares, Michael J. McCall, PubMed EngineeringOncologic ImagingImaging AgentImmunologyPathology	1988	193
Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent Min K. Moi, Claude F. Meares, Michael J. McCall, Analytical Biochemistry Inorganic ChemistryBiochemistryNatural SciencesCoordination ComplexBioorganometallic Chemistry	1985	193
Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. S.V. Deshpande, Sally J. DeNardo, David L. Kukis, PubMed ImmunologyBiological TherapyImmunotherapeuticsImmunotherapyTumor Uptake	1990	150
Comparative serum stability of radiochelates for antibody radiopharmaceuticals. William C. Cole, Sally J. DeNardo, Claude F. Meares, PubMed Immunocytochemical TechniqueSerum IncubationImmunologyChemical BiologyImmunotherapy	1987	108
Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. Shrikant Deshpande, Sally J. DeNardo, Claude F. Meares, PubMed Cancer TherapyImmunologyImmunoeditingImmunotherapyOncology	1988	102
Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane Michael J. McCall, Habibe Diril, Claude F. Meares Bioconjugate Chemistry	1990	99
Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Christos Kosmas, D Snook, Calvin S. R. Gooden, PubMed Humoral Immune ResponsesImmunologyPathologyImmunotherapeuticsCancer Patients	1992	85
Macrocyclic chelates of radiometals for diagnosis and therapy. Claude F. Meares, Min K. Moi, Halit Diril, PubMed EngineeringImmunotherapyNanomedicineMedicinal ChemistryTheranostics	1990	56
Metabolizable 111in chelate conjugated anti-idiotype monoclonal antibody for radioimmunodetection of lymphoma in mice Michael K. Haseman, David A. Goodwin, Claude F. Meares, European Journal of Nuclear Medicine and Molecular Imaging Lymphoid NeoplasiaCancer ImmunosurveillanceImmunologyPathologyAnti-idiotype Monoclonal Antibody	1986	53

Page 1